Retinoic acid-related orphan receptor alpha reprograms glucose metabolism in glutamine-deficient hepatoma cells

Hepatology

Volumn 61, Issue 3, 2015, Pages 953-964

  Byun, Jun Kyu ^a   Choi, Yeon Kyung ^a,b   Kang, Yu Na ^c   Jang, Byoung Kuk ^c   Kang, Koo Jeong ^c   Jeon, Yong Hyun ^a,b   Lee, Ho Won ^a,b   Jeon, Jae Han ^a,b   Koo, Seung Hoi ^d   Jeong, Won Il ^e   Harris, Robert A ^f   Lee, In Kyu ^a,b   Park, Keun Gyu ^a,b  

^a Kyungpook National University Hospital   (South Korea)

^b Kyungpook National University School of Medicine   (South Korea)

^c Keimyung University School of Medicine   (South Korea)

^d Korea University   (South Korea)

^e Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^f INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; GLUTAMINE; GLUTATHIONE; GLUTATHIONE DISULFIDE; GLYCEROL 3 PHOSPHATE DEHYDROGENASE; GLYCEROL 3 PHOSPHATE DEHYDROGENASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; PHOSPHOGLYCERATE DEHYDROGENASE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 3; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 4; PROTEIN P21; PROTEIN P53; PYRUVATE DEHYDROGENASE KINASE 2; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; RETINOIC ACID; RETINOID RELATED ORPHAN RECEPTOR ALPHA; SMALL INTERFERING RNA; THIOREDOXIN INTERACTING PROTEIN; TRANSCRIPTION FACTOR E2F; UNCLASSIFIED DRUG; ADENOSINE TRIPHOSPHATE; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; GLUCOSE; PROTEIN SERINE THREONINE KINASE; PYRUVATE DEHYDROGENASE (ACETYL-TRANSFERRING) KINASE; RORA PROTEIN, HUMAN; TP53 PROTEIN, HUMAN;

ADENOVIRIDAE; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOSYNTHESIS; CANCER INHIBITION; CANCER SIZE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME PHOSPHORYLATION; FEMALE; GENE OVEREXPRESSION; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLUCOSE UTILIZATION; GLYCOLYSIS; HEPATOCELLULAR CARCINOMA CELL LINE; HEPATOMA CELL; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; OXIDATION; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; PROMOTER REGION; UPREGULATION; AGED; ANTAGONISTS AND INHIBITORS; DEFICIENCY; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ADENOSINE TRIPHOSPHATE; ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; GLUCOSE; GLUTAMINE; GLYCOLYSIS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NUCLEAR RECEPTOR SUBFAMILY 1, GROUP F, MEMBER 1; PROTEIN-SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84923310390     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27577     Document Type: Article

References (26)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-2917.
2. Herzog CE, Andrassy RJ, Eftekhari F. Childhood cancers: hepatoblastoma. Oncologist 2000;5:445-453.
3. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-1022.
4. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
5. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
6. Sivaprakasam P, Gupta AA, Greenberg ML, Capra M, Nathan PC. Survival and long-term outcomes in children with hepatoblastoma treated with continuous infusion of cisplatin and doxorubicin. J Pediatr Hematol Oncol 2011;33:e226-e230.
7. Vander Heiden MG. Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov 2011;10:671-684.
8. Dang CV. MYC, metabolism, cell growth, and tumorigenesis. Cold Spring Harb Perspect Med 2013;3:a014217.
9. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008;7:11-20.
10. DeBerardinis RJ, Cheng T. Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 2010;29:313-324.
11. DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M, Wehrli S, Thompson CB. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci U S A 2007;104:19345-19350.
12. Shanware NP, Mullen AR, DeBerardinis RJ, Abraham RT. Glutamine: pleiotropic roles in tumor growth and stress resistance. J Mol Med (Berl) 2011;89:229-236.
13. Qing G, Li B, Vu A, Skuli N, Walton ZE, Liu X, et al. ATF4 regulates MYC-mediated neuroblastoma cell death upon glutamine deprivation. Cancer Cell 2012;22:631-644.
14. Taylor L, Curthoys NP. Glutamine metabolism: role in acid-base balance. Biochem Mol Biol Educ 2004;32:291-304.
15. Baek SH, Kim KI. Emerging roles of orphan nuclear receptors in cancer. Annu Rev Physiol 2014;76:177-195.
16. Pearen MA, Muscat GE. Orphan nuclear receptors and the regulation of nutrient metabolism: understanding obesity. Physiology (Bethesda) 2012;27:156-166.
17. Jetten AM. Retinoid-related orphan receptors (RORs): critical roles in development, immunity, circadian rhythm, and cellular metabolism. Nucl Recept Signal 2009;7:e003.
18. Kim H, Lee JM, Lee G, Bhin J, Oh SK, Kim K, et al. DNA damage-induced RORalpha is crucial for p53 stabilization and increased apoptosis. Mol Cell 2011;44:797-810.
19. Lee JM, Kim IS, Kim H, Lee JS, Kim K, Yim HY, et al. RORalpha attenuates Wnt/beta-catenin signaling by PKCalpha-dependent phosphorylation in colon cancer. Mol Cell 2010;37:183-195.
20. Contractor T, Harris CR. p53 negatively regulates transcription of the pyruvate dehydrogenase kinase Pdk2. Cancer Res 2012;72:560-567.
21. Steinman RA, Huang J, Yaroslavskiy B, Goff JP, Ball ED, Nguyen A. Regulation of p21(WAF1) expression during normal myeloid differentiation. Blood 1998;91:4531-4542.
22. Park KK, Deok Ahn J, Lee IK, Magae J, Heintz NH, Kwak JY, et al. Inhibitory effects of novel E2F decoy oligodeoxynucleotides on mesangial cell proliferation by coexpression of E2F/DP. Biochem Biophys Res Commun 2003;308:689-697.
23. Yuneva MO, Fan TW, Allen TD, Higashi RM, Ferraris DV, Tsukamoto T, et al. The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. Cell Metab 2012;15:157-170.
24. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009;324:1029-1033.
25. Schulze A, Harris AL. How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature 2012;491:364-373.
26. Son J, Lyssiotis CA, Ying H, Wang X, Hua S, Ligorio M, et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 2013;496:101-105.